Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TDO2 | P48775 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651178 | 1.00 | KMT2A (0.40) | KMT2AIDO1TDO2EPHX1THRB | |
| SCHEMBL31499299 | 0.85 | KMT2A (0.40) | KMT2AIDO1TDO2EPHX1THRB | |
| SCHEMBL5503227 | 0.81 | KMT2A (0.38) | KMT2AIDO1TDO2EPHX1THRB | |
| SCHEMBL546542 | 0.81 | KMT2A (0.38) | KMT2AIDO1TDO2EPHX1THRB | |
| SCHEMBL8932556 | 0.79 | TAAR1 (0.50) | TSHRTAAR1KDM4ELMNAPMP22 | |
| SCHEMBL24002249 | 0.78 | THRB (0.38) | KMT2AEPHX1THRBALDH1A1TAAR1 | |
| SCHEMBL28931191 | 0.75 | IDO1 (0.48) | IDO1TDO2DPP4F2TAAR1 | |
| SCHEMBL20054801 | 0.74 | KMT2A (0.46) | KMT2AALDH1A1MAPK1TSHRLMNA | |
| SCHEMBL24243366 | 0.74 | LMNA (0.36) | KMT2AEPHX1THRBTDP1ALDH1A1 | |
| Methylene Chloride SCHEMBL28192145 | 0.74 | KMT2A (0.33) | KMT2AEPHX1THRBTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197551-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-12-28 | — | — | EP | disclosed |
| US-8586020-B2 | Poly(organophosphazene) composition for biomaterials | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-11-19 | — | — | US | disclosed |
| US-8455638-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| EP-2197551-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2010-06-23 | — | — | EP | disclosed |
| EP-2125727-A1 | STABLE S-NITROSOTHIOLS, METHOD OF SYNTHESIS AND USE | LACER, S.A. (ES) | 2009-12-02 | — | — | EP | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| WO-2009032249-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK & CO., INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2008080934-A1 | STABLE S-NITROSOTHIOLS, METHOD OF SYNTHESIS AND USE | LÁCER, S.A. (ES) | 2008-07-10 | — | — | WO | disclosed |
| EP-1648880-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | Euro-Celtique S.A. (LU) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012287-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-02-10 | — | — | WO | disclosed |
| EP-0873123-A4 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 1999-02-03 | — | — | EP | disclosed |
| EP-0873123-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997017070-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1997-05-15 | — | — | WO | disclosed |
| WO-1996014873-A2 | COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY | SRI INTERNATIONAL (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A2, GUCY1A1 | KMT2A 4012/4885IDO1 4346/4885TDO2 4662/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | KMT2A 4012/4885IDO1 4346/4885TDO2 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.